Preemptive Bone Marrow Transplantation for FANCD1/BRCA2.

Area of Science:

• Pediatric Oncology
• Hematology
• Genetics

Background:

• Children with biallelic FANCD1/BRCA2 mutations face high risks of leukemia and solid tumors.
• Preemptive bone marrow transplantation (PE-BMT) is a potential strategy to prevent leukemia in these high-risk children.
• Empirical studies on PE-BMT are challenging due to the rarity of affected children and uncertain benefits.

Purpose of the Study:

• To estimate leukemia risks and potential survival gains with curative PE-BMT in children with FANCD1/BRCA2 mutations.
• To explore the feasibility and benefits of PE-BMT using a decision analysis model considering age at diagnosis and transplantation-related mortality.
• To provide clinical guidance for managing this rare genetic disorder.

Main Methods:

• Survival analysis was employed to estimate leukemia risks and expected survival post-leukemia elimination.
• A decision analysis model was developed to assess PE-BMT plausibility across different ages and transplantation risks.
• Simulations were conducted to quantify survival improvements under various scenarios.

Main Results:

• PE-BMT at 1 year of age with a 10% transplantation-related mortality risk could increase mean survival by 1.7 years.
• The most significant survival benefit from PE-BMT was observed for children diagnosed between 1 and 3 years of age.
• Beyond 3 years of age at diagnosis, the benefit of PE-BMT diminished, with solid tumor mortality becoming a more prominent concern.

Conclusions:

• PE-BMT is a plausible intervention that can improve survival for children with FANCD1/BRCA2 mutations, particularly when initiated early.
• The optimal timing for PE-BMT is between 1 and 3 years of age, balancing leukemia prevention against transplantation risks.
• The modeling approach can be adapted for other hematologic disorders lacking extensive empirical data, aiding clinical decision-making.